中国医药
(600056)
| 流通市值：150.58亿 | | | 总市值：150.64亿 |
| 流通股本：14.95亿 | | | 总股本：14.96亿 |
| 报告期 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 8,188,780,055.69 | 35,361,621,734.95 | 25,894,435,068.47 | 17,075,860,112.16 |
| 营业收入 | 8,188,780,055.69 | 35,361,621,734.95 | 25,894,435,068.47 | 17,075,860,112.16 |
| 二、营业总成本 | 7,879,789,178.24 | 34,112,387,650.65 | 24,983,221,781.2 | 16,438,279,511.82 |
| 营业成本 | 7,319,970,471.56 | 31,647,847,213.84 | 23,203,636,876.96 | 15,294,245,978.33 |
| 税金及附加 | 24,131,082.9 | 103,927,929.4 | 74,542,890.22 | 53,434,403.39 |
| 销售费用 | 198,533,489.95 | 1,014,532,766.54 | 759,476,994.57 | 494,676,658.69 |
| 管理费用 | 273,131,624.27 | 1,077,687,896.07 | 808,421,513.7 | 540,068,919.01 |
| 研发费用 | 34,579,994.99 | 158,375,583.87 | 102,129,979.68 | 65,629,033.38 |
| 财务费用 | 29,442,514.57 | 110,016,260.93 | 35,013,526.07 | -9,775,480.98 |
| 其中:利息费用 | 31,638,233.61 | 197,025,891.51 | 111,295,105.66 | 88,140,694.75 |
| 其中:利息收入 | 21,995,446.48 | 34,826,067.57 | 46,795,986.17 | 30,585,943.37 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 0 | -2,210,527.65 | 5,891,042.55 | 5,891,042.55 |
| 加:投资收益 | 7,615,328.46 | -68,010,210.63 | 12,899,531.91 | 9,456,884.26 |
| 资产处置收益 | 1,796,810.37 | 10,529,773.61 | 6,962,420.84 | 7,371,175.2 |
| 资产减值损失(新) | 3,437.5 | -150,703,551.68 | -62,486.49 | 265,715.11 |
| 信用减值损失(新) | -10,739,878.14 | -69,529,640.29 | -151,790,370.16 | -152,062,098.56 |
| 其他收益 | 5,073,425.99 | 53,678,276.72 | 38,649,220.27 | 16,366,929.96 |
| 四、营业利润 | 312,740,001.63 | 1,022,988,204.38 | 823,762,646.19 | 524,870,248.86 |
| 加:营业外收入 | 3,731,081.52 | 27,021,333.23 | 10,349,733.82 | 4,683,722.03 |
| 减:营业外支出 | 2,163,292.64 | 50,714,740.99 | 11,664,674.55 | 8,831,542.5 |
| 五、利润总额 | 314,307,790.51 | 999,294,796.62 | 822,447,705.46 | 520,722,428.39 |
| 减:所得税费用 | 77,168,271.98 | 324,658,952.78 | 233,736,960.4 | 145,395,307.93 |
| 六、净利润 | 237,139,518.53 | 674,635,843.84 | 588,710,745.06 | 375,327,120.46 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 237,139,518.53 | 674,635,843.84 | 588,710,745.06 | 375,327,120.46 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 182,197,132.89 | 473,229,055.14 | 454,763,908.45 | 293,959,402.72 |
| 少数股东损益 | 54,942,385.64 | 201,406,788.7 | 133,946,836.61 | 81,367,717.74 |
| 扣除非经常损益后的净利润 | 177,482,096.4 | 376,478,717.77 | 394,415,899.55 | 255,736,026.62 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.12 | 0.32 | 0.3 | 0.2 |
| (二)稀释每股收益 | 0.12 | 0.32 | 0.3 | 0.2 |
| 八、其他综合收益 | -1,525,891.19 | -8,387,833.07 | 613,986.04 | 2,628,805.36 |
| 归属于母公司股东的其他综合收益 | -1,525,891.19 | -8,511,106.43 | 613,986.04 | 2,628,805.36 |
| 九、综合收益总额 | 235,613,627.34 | 666,248,010.77 | 589,324,731.1 | 377,955,925.82 |
| 归属于母公司股东的综合收益总额 | 180,671,241.7 | 464,717,948.71 | 455,377,894.49 | 296,588,208.08 |
| 归属于少数股东的综合收益总额 | 54,942,385.64 | 201,530,062.06 | 133,946,836.61 | 81,367,717.74 |
| 公告日期 | 2026-04-29 | 2026-04-25 | 2025-10-28 | 2025-08-28 |
| 审计意见(境内) | | 标准无保留意见 | | |